Abstract
Diabetic dyslipidemia is due to a multiple array of metabolic abnormalities determining a typical phenotype characterized by increased plasma triglycerides, reduced HDL and a preponderance of small, dense LDL. This dyslipidemia, defined as atherogenic dyslipidemia, is thought to be highly responsible for the increased cardiovascular risk in diabetes mellitus. Several lines of evidence indicate that the increased liver production of VLDL is the main underlying defect in atherogenic dyslipidemia. This review will recapitulate the pathophysiological aspects of diabetic dyslipidemia with special focus on the molecular mechanism causing increased liver production of VLDL in diabetic patients. The consequences of atherogenic dyslipidemia on mechanisms of atherogenesis will be also reviewed.
Keywords: Atherogenic dyslipidemia, VLDL secretion, apoB metabolism, insulin resistance
Current Vascular Pharmacology
Title:Mechanisms of Diabetic Dyslipidemia: Relevance for Atherogenesis
Volume: 10 Issue: 6
Author(s): Marcello Arca, Giovanni Pigna and Carla Favoccia
Affiliation:
Keywords: Atherogenic dyslipidemia, VLDL secretion, apoB metabolism, insulin resistance
Abstract: Diabetic dyslipidemia is due to a multiple array of metabolic abnormalities determining a typical phenotype characterized by increased plasma triglycerides, reduced HDL and a preponderance of small, dense LDL. This dyslipidemia, defined as atherogenic dyslipidemia, is thought to be highly responsible for the increased cardiovascular risk in diabetes mellitus. Several lines of evidence indicate that the increased liver production of VLDL is the main underlying defect in atherogenic dyslipidemia. This review will recapitulate the pathophysiological aspects of diabetic dyslipidemia with special focus on the molecular mechanism causing increased liver production of VLDL in diabetic patients. The consequences of atherogenic dyslipidemia on mechanisms of atherogenesis will be also reviewed.
Export Options
About this article
Cite this article as:
Arca Marcello, Pigna Giovanni and Favoccia Carla, Mechanisms of Diabetic Dyslipidemia: Relevance for Atherogenesis, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520864
DOI https://dx.doi.org/10.2174/157016112803520864 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Islet-, Gut-, and Adipocyte-Derived Hormones in the Central Control of Food Intake and Body Weight: Implications for an Integrated Neurohormonal Approach to Obesity Pharmacotherapy
Current Diabetes Reviews A Mendelian Randomization Study on Infant Length and Type 2 Diabetes Mellitus Risk
Current Gene Therapy Glycation of Human Serum Albumin in Diabetes: Impacts on the Structure and Function
Current Medicinal Chemistry A Possible Placental Factor for Preeclampsia: sFlt-1
Current Medicinal Chemistry Risk Factors for Heart Failure Progression and Outcomes
Current Cardiology Reviews Endothelial Changes in Individuals with Prehypertension
Current Hypertension Reviews Strategies Targeting Soluble β-Amyloid Oligomers and their Application to Early Diagnosis of Alzheimer’s Disease
Current Alzheimer Research Non-Demented Individuals with Alzheimer’s Disease Neuropathology: Resistance to Cognitive Decline May Reveal New Treatment Strategies
Current Pharmaceutical Design Advances in Antidiabetic Drugs Targeting Insulin Secretion
Current Pharmaceutical Design Hypolipidemic, Antioxidant and Cardioprotective Effects of the Aqueous Extract from <i>Scorzanera Undulata</i> Tubers in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Anti-Vascular Endothelial Growth Factor Drug Treatment of Diabetic Macular Edema: The Evolution Continues
Current Diabetes Reviews Diabetes and Chronic Heart Failure: From Diabetic Cardiomyopathy to Therapeutic Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets Synthesis, Characterization and <i>in vivo</i> Evaluation of PEGylated PPI Dendrimer for Safe and Prolonged Delivery of Insulin
Drug Delivery Letters Preventing Type 2 Diabetes in High Risk Patients: An Overview of Lifestyle and Pharmacological Measures
Current Drug Targets The Role of Zinc and Copper in Insulin Resistance and Diabetes Mellitus
Current Medicinal Chemistry Acute Myocardial Infarction: High Risk Ventricular Tachyarrhythmias and Admission Glucose Level in Patients with and without Diabetes Mellitus
Current Diabetes Reviews Emerging Potential of Citrus Flavanones as an Antioxidant in Diabetes and its Complications
Current Topics in Medicinal Chemistry Editorial: Targeting Cerebral Vascular Injury for Intervention
Current Drug Delivery Role of Endothelin in Diabetic Retinopathy
Current Vascular Pharmacology Evaluation of Oxidative Status with Exhaled Breath 8-isoprostane Levels in Patients with Hyperthyroidism
Endocrine, Metabolic & Immune Disorders - Drug Targets